# A Study of RSLV-132 in Females With Sjögren's Disease

> **NCT06440525** · PHASE2 · RECRUITING · sponsor: **Resolve Therapeutics** · enrollment: 106 (estimated)

## Conditions studied

- Primary Sjögren Syndrome

## Interventions

- **DRUG:** RSLV-132
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06440525
- **Lead sponsor:** Resolve Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06440525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06440525, "A Study of RSLV-132 in Females With Sjögren's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06440525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*